Efficacy of primary topical 0.02% Mitomycin C for The Treatment of Conjunctiva - Corneal Intraepithelial Neoplasia
Article Sidebar
Main Article Content
Abstract
BACKGROUND: The gold standard treatment for conjunctiva - corneal intraepithelial neoplasia (CCIN) is wide excision and double freeze - thaw cryotherapy. In diffuse lesions or multiple tumors, an adequately wide excision is difficult to achieve.
OBJECTIVES: To study the efficacy of primary topical 0.02% mitomycin C for the treatment of conjunctiva - corneal intraepithelial neoplasia (CCIN).
METHODS: This is an intervention with historical controlled case - series. In this study, we compared the outcomes of patients with CCIN treated with primary topical 0.02% mitomycin C (four times daily, 7 - day on and 7 - day off regimen) and historical patients treated by excision. The primary outcome was the complete resolution of CCIN.
RESULTS: Eleven patients were treated with 0.02% topical mitomycin C, and complete resolution was achieved in nine (81.8%) patients. The median time to resolution was 7.7 weeks. Two (18.2%) patients had partial resolution and recommended for surgery. There was no recurrence in complete resolution group. The mean follow - up time of 19.4 months (range 6 – 40.7 months). In the surgical group, complete resolution was achieved in 10 (100%) patients and two out of 10 patients experienced recurrence. The mean follow - up time was 28.6 months (range, 3.6 – 78.2 months). The short-term complication was punctate epithelial erosion.
CONCLUSIONS: Primary topical 0.02% mitomycin C seemed to be effective in treating CCIN.
Article Details
References
Tananuvat N, Lertprasertsuke N. Ocular surface squamous neoplasia. In: Srivastava S,editor. Intraepithelial Neoplasia. London: IntechOpen; 2012. p 35-62.
Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, et al. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea 2005 ;24:443-8.
Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthalmic Plast Reconstr Surg 2009;25:296-9.
Daniell M, Maini R, Tole D. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol 2002;30:94-8.
Pombejara NF, Tulvatana W, Pungpapong K. Malignant tumors of the eye and ocular adnexa in Thailand: a six year review at King Chulalongkorn Memorial Hospital. Asian Biomedicine 2009;3: 551-5.
Tangpakasit W, Reanpinyawat T, Bhornmata A. A case report: squamous cell carcinoma of conjunctiva. Thammasat Thai Journal of Ophthalmology 2014;9(2):1-5.
Gupta A, Muecke J. Treatment of ocular surface squamous neoplasia with mitomycin C. Br J Ophthalmol 2010;94:555-8.
Kusumesh R, Ambastha A, Kumar S, Sinha BP, Imam N. Retrospective comparative study of topical interferon α2b Versus Mitomycin C for primary ocular surface squamous neoplasia. Cornea 2017;36:327-31.
Manoher JM, Kochar A, Chauhan A. Topical 0.02% Mitomycin C for management of primary corneal conjunctival intraepithelial neoplasia as primary therapy: a long term follow up. IAIM 2016;3(8):16-22.
Yamamoto N, Ohmura T, Suzuki H, Shirasawa H. Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology 2002;109: 249-52.
Kaliki S, Singh S, Iram S, Tripuraneni D. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients. Indian J Ophthalmol 2016;64:702-9.
Besley J, Pappalardo J, Lee GA, Hirst LW, Vincent SJ. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b. Am J Ophthalmol 2014;157:287-93.
Moon J, Choi SH, Lee MJ, Jo DH, Park UC, Yoon SO, et al. Ocular surface complications of local anticancer drugs for treatment of ocular tumors. Ocul Surf 2021;19:16-30.
Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 2010; 94:1316-21.
Dudney BW, Malecha MA. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Am J Ophthalmol 2004 ;137: 950-1.